Literature DB >> 17703128

PPAR activation: a new target for the treatment of hypertension.

Eyal Leibovitz1, Ernesto L Schiffrin.   

Abstract

Hypertensive patients are at increased risk for cardiovascular complications. Inhibition of different pathophysiological mechanisms involved in hypertension and hypertension-related target organ damage may revert or prevent the progression of the pathological changes observed and reduce the occurrence of cardiovascular events. One of the new targets that may prevent or regress hypertensive vascular, renal, and perhaps brain changes in hypertension is the activation of nuclear receptors that have metabolic effects but also exert antiinflammatory action, the peroxisome proliferator activator receptor (PPAR) activators alpha and gamma. This review will discuss some of the evidence, both experimental and clinical, that suggests that activation of PPAR alpha and/or gamma in hypertension may exert beneficial cardiovascular protective effects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17703128     DOI: 10.1097/FJC.0b013e318062153b

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  11 in total

Review 1.  Angiotensin II AT(1) receptor blockers as treatments for inflammatory brain disorders.

Authors:  Juan M Saavedra
Journal:  Clin Sci (Lond)       Date:  2012-11       Impact factor: 6.124

2.  Haplotype analysis of PPARγ C681G and intron CT variants. Positive association with essential hypertension.

Authors:  Q Zhu; Z Guo; X Hu; M Wu; Q Chen; W Luo; J Liu
Journal:  Herz       Date:  2013-05-09       Impact factor: 1.443

3.  Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-activated receptor-γ activation in human monocytes.

Authors:  Tao Pang; Julius Benicky; Juan Wang; Martina Orecna; Enrique Sanchez-Lemus; Juan M Saavedra
Journal:  J Hypertens       Date:  2012-01       Impact factor: 4.844

4.  Proteomic analysis yields an unexpected trans-acting point in control of the human sympathochromaffin phenotype.

Authors:  Stéphane Chiron; Zhiyun Wei; Yuqing Chen; Kuixing Zhang; Gen Wen; Wolfgang H Fischer; Sushil K Mahata; Daniel T O'Connor
Journal:  Circ Cardiovasc Genet       Date:  2011-05-06

Review 5.  Vascular effects of antihypertensive drug therapy.

Authors:  Asia Rehman; Ernesto L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

Review 6.  The pathophysiology of hypertension in systemic lupus erythematosus.

Authors:  Michael J Ryan
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-01-21       Impact factor: 3.619

Review 7.  Peroxisome proliferator-activated receptors for hypertension.

Authors:  Daisuke Usuda; Tsugiyasu Kanda
Journal:  World J Cardiol       Date:  2014-08-26

8.  Association of PPAR-γ2 and β3-AR Polymorphisms With Postmenopausal Hypertension.

Authors:  Bogna Grygiel-Górniak; Elżbieta Kaczmarek; Maria Mosor; Juliusz Przysławski; Jerzy Nowak
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-03-31       Impact factor: 3.738

9.  Open-label, Randomized Crossover Study Between Telmisartan and Valsartan on Improving Insulin Resistance and Adipocytokines in Nondiabetic Patients with Mild Hypertension.

Authors:  Hiroyuki Ohbayashi; Shinya Minatoguchi; Takuma Aoyama; Hisayoshi Fujiwara
Journal:  J Rural Med       Date:  2010

10.  Fenretinide inhibits macrophage inflammatory mediators and controls hypertension in spontaneously hypertensive rats via the peroxisome proliferator-activated receptor gamma pathway.

Authors:  Ching-Han Lin; Shang-Yu Lee; Chun-Cheng Zhang; Ye-Fong Du; Hao-Chang Hung; Hung-Tsung Wu; Horng-Yih Ou
Journal:  Drug Des Devel Ther       Date:  2016-11-01       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.